LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
POCI
Precision Optics Corporation, Inc.
There isn't enough reported data to score POCI yet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
POCI Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Under pressure | |
| Under pressure | |
| Weak |
POCI's revenue is currently strong, but its profitability, cash flow and balance sheet are under pressure.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
POCI PE Valuation
POCI has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
POCI Forward outlook
There aren't enough analyst estimates for POCI to show an outlook.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the stronger earnings trend. Trailing diluted EPS is up 51% for LLY versus POCI down 172%.
POCI Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q1 2026 | -$0.64 | +$0.25 |
| Q4 2025 | -$0.93 | -$0.29 |
| Q3 2025 | -$0.85 | -$0.23 |
| Q2 2025 | -$0.85 | -$0.36 |
| Q1 2025 | -$0.89 | -$0.61 |
| Q4 2024 | -$0.64 | -$0.34 |
| Q3 2024 | -$0.62 | -$0.56 |
| Q2 2024 | -$0.49 | -2550% |
POCI lost $0.64 per share over the past year, a smaller loss than the year before.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over POCI on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over POCI on profitability, with a higher operating margin.
POCI Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $8.8M | +42% |
| Q1 2026 | $8.7M | +108% |
| Q4 2025 | $7.4M | +63% |
| Q3 2025 | $6.7M | +59% |
| Q2 2025 | $6.2M | +31% |
| Q1 2025 | $4.2M | -20% |
| Q4 2024 | $4.5M | -6.2% |
| Q3 2024 | $4.2M | -2.9% |
POCI's revenue has grown year over year for five quarters in a row: $9M last quarter, up 42% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -1.2% | +21 points |
| Q1 2026 | -0.7% | +48 points |
| Q4 2025 | -24% | -3.5 points |
| Q3 2025 | -24% | +5.8 points |
| Q2 2025 | -22% | +6.8 points |
| Q1 2025 | -49% | -44 points |
| Q4 2024 | -20% | -5.5 points |
| Q3 2024 | -30% | -20 points |
POCI's operating margin was −1.2% last quarter, up 21 points from the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the stronger cash trend. Its trailing FCF is up 259% versus its history, compared with POCI at down 5%.
POCI Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q1 2026 | -$723.3K | +$1.3M |
| Q4 2025 | -$256.1K | +$560.6K |
| Q3 2025 | $78.2K | +$421.2K |
| Q2 2025 | -$615.5K | +$372.2K |
| Q1 2025 | -$2M | -$1.7M |
| Q4 2024 | -$816.6K | -$575.3K |
| Q3 2024 | -$343K | +$1.1M |
| Q2 2024 | -$987.6K | -$395.8K |
POCI has burned cash in most quarters: −$2M over the past year, against −$4M the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over POCI on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
POCI Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1% | +79.5K shares |
| 1 year | +13% | +877K shares |
| 3 years | +38% | +2.2M shares |
| 5 years | +66% | +3.1M shares |
| Available history | +82% | +3.5M shares |
POCI has 8M diluted shares, up 13% from a year ago.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
POCI Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2022 | 4.6x | High |
POCI's net debt is about 4.6 years of its operating earnings (EBITDA).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
POCI Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.5 | Neutral |
| Stochastic | 69.4 | Neutral |
POCI's weekly RSI is 59 (neutral) and its Stochastic is 69 (neutral).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
POCI PE vs Healthcare Sector
| Metric | POCI | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
POCI has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over POCI on trend strength, trading above more of its moving averages.
POCI Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $4.61 | 8.5% above |
| 20 week MA | $4.53 | 10% above |
| 50 week MA | $4.60 | 8.7% above |
| 100 week MA | $4.59 | 8.9% above |
| 200 week MA | $5.26 | 4.9% below |
POCI has bounced recently, but its long-term trend is still down: it's above its 8-, 20-, 50- and 100-week averages, but 4.9% below its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over POCI on returns for 2026, with the stronger performance.
POCI Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $5.40 | $4.20 | -22% |
| 2021 | $4.20 | $7.20 | +71% |
| 2022 | $7.20 | $5.55 | -23% |
| 2023 | $5.55 | $6.02 | +8.5% |
| 2024 | $6.02 | $5.01 | -17% |
| 2025 | $5.01 | $4.21 | -16% |
| 2026 YTD | $4.21 | $5.00 | +19% |
POCI has finished lower in four of the last six years. It's up 19% so far in 2026.